Open‐Label, Phase II Study to Assess the Efficacy and Safety of Canakinumab Treatment in Active Hyperimmunoglobulinemia D With Periodic Fever Syndrome - Concepedia

Concepedia

Publication | Closed Access

Open‐Label, Phase II Study to Assess the Efficacy and Safety of Canakinumab Treatment in Active Hyperimmunoglobulinemia D With Periodic Fever Syndrome

57

Citations

40

References

2017

Year

Juan I. Aróstegui, Jordi Antón, Inmaculada Calvo, Ángel Robles‐Marhuenda, E. Iglesias, Berta López‐Montesinos, Romain Banchereau, Seunghee Hong, Y. Joubert, G. Junge,

Arthritis & Rheumatology

Abstract

The results of this study demonstrate the efficacy and safety of canakinumab treatment to control active HIDS and to suppress inflammation-related transcriptional responses.

References

	Year	Citations

Page 1